Connect with us

Business Wire

Molecular Tagging of Pharmaceutical Drugs Utilizing Applied DNA’s Technology Published in Peer-Reviewed Journal

Business Wire

Published

on

Reading Time: 3 minutes

PLOS ONE Publication Details Proprietary Method to Distinguish
Legitimate Pharmaceutical Drugs from Counterfeit Products Including
Counterfeit Opioids

STONY BROOK, N.Y.–(BUSINESS WIRE)–$apdn #authenticityApplied
DNA Sciences
, Inc. (NASDAQ: APDN), announced today that its
scientific paper entitled, Rapid
authentication of pharmaceuticals via DNA tagging and field detection
,
has been published in the June 2019 edition of PLOS ONE,
detailing a novel Physical-Chemical
Identifier (PCID)
to authenticate and track legitimate
pharmaceutical products through the pharmaceutical supply chain.

The paper summarizes a study in which a pharmaceutical manufacturer
tagged acetaminophen capsules with pharmaceutical-grade ink containing a
unique DNA tag produced by Applied DNA and its subsequent
authentication. Study results indicate that authentication can be
performed reliably in a laboratory or in the field utilizing easy to use
portable devices, and proves that Applied DNA’s SigNature®
Molecular Tag can be safely introduced onto the surface of a capsule in
ordinary pharmaceutical ink. The patent-pending, user-friendly method
and system showed the molecular tag can be read at any time after
simple, non-destructive swabbing.

“We believe DNA tagging of inks, coatings, and other ingredients can be
used in the pharmaceutical supply chain, securing authenticity of an
individual dose from the manufacturer, to the distributor, and finally
the pharmacy. Authentication is possible, even when the product is
separated from packaging, making it a solid complement to serialization
and a platform to be considered as a weapon against today’s most
difficult challenges, such as the opioid crisis,” said Dr. James
Hayward, president and CEO, Applied DNA.

Drug
overdose deaths in the United States are at unprecedented levels
,
with synthetic opioids increasingly implicated in overdoses, and the World
Health Organization (WHO) estimates that 1-in-10 medical products
circulating
in low- and middle-income countries is either substandard or falsified.

“Counterfeit drugs represent a large and growing problem for the global
pharmaceutical industry, and can lead to serious illness or death.
Publication of our methods and systems for molecular tagging of
pharmaceuticals is a seminal development in our industrial deployment,
and acceptance of our methods by scientific peers is a welcome
endorsement,” said Dr. Michael Hogan, vice president, Life Sciences,
Applied DNA.

About PLOS ONE

The world’s first multidisciplinary Open Access journal, PLOS
ONE accepts scientifically rigorous research, regardless of novelty.
PLOS ONE’s broad scope provides a platform to publish primary research
including interdisciplinary and replication studies as well as negative
results. The journal’s publication criteria are based on high ethical
standards and the rigor of the methodology and conclusions reported.

About Applied DNA Sciences

Applied DNA is a provider of molecular technologies that enable supply
chain security, anti-counterfeiting and anti-theft technology, product
genotyping and pre-clinical nucleic acid-based therapeutic drug
candidates.

Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help protect
products, brands, entire supply chains, and intellectual property of
companies, governments and consumers from theft, counterfeiting, fraud
and diversion.

Visit adnas.com
for more information. Follow us on Twitter
and LinkedIn.
Join our mailing
list
.

Common stock listed on NASDAQ under the symbol APDN, and warrants are
listed under the symbol APDNW.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of the Private Securities
Litigation Act of 1995. Forward-looking statements describe Applied
DNA’s future plans, projections, strategies and expectations, and are
based on assumptions and involve a number of risks and uncertainties,
many of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to its history of net
losses, limited financial resources, limited market acceptance,
uncertainties relating to its ability to maintain its NASDAQ listing,
uncertainties relating to receiving regulatory clearance from the U.S.
Food and Drug Administration or equivalent foreign regulatory agencies
and various other factors detailed from time to time in Applied DNA’s
SEC reports and filings, including our Annual Report on Form 10-K filed
on December 18, 2018 and our subsequent quarterly reports on Form 10-Q
filed on February 7, 2019 and May 9, 2019, and other reports we file
with the SEC, which are available at www.sec.gov.
Applied DNA undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date hereof to reflect the occurrence of
unanticipated events, unless otherwise required by law.

Contacts

investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777,
shurry@lhai.com
program
contacts
: Dr. Michael Hogan, Vice President, Life Sciences,
631-240-8820, mike.hogan@adnas.com
web:
www.adnas.com
twitter:
@APDN

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

For the last half century, thousands of communications professionals have turned to us to deliver their news to the audiences most important to their business through the sources they trust most. Over that time, we've gone from a single office with one full time employee to more than 500 employees in 32 bureaus.

Business Wire

Bin Zayed Group’s global oil chain and BBOSS reached a strategic cooperation

Business Wire

Published

on

Reading Time: 2 minutes

NEW YORK–(BUSINESS WIRE)–Recently, Top investment master in the world, Prince of Abu Dhabi, Chairman of the Board of Directors of the Bin Zayed Group, His Excellency Sheikh Khaled Bing Zayed Al Nahyan, Chairman of the Board of Directors of the Abu Dhabi Sovereign Fund, chaired the “Global refueling chain OPC Strategic Cooperation Seminar” in Bangkok, Thailand. The Bin Zayed Group, a partner from 50 countries around the world, held a one-day strategic discussion on the use of the BBOSS accounting tool to launch the global refueling chain. Finally reached a consensus that the OPC global refueling system uses the BBOSS accounting tool as a third-party tool for OPC points.

Liu Shijiang, secretary general of the China Aviation Rescue Alliance, attended the seminar and reached a strategic cooperation intention on the cooperation between the Air Rescue Association and OPC.

(BIN ZAYED GROUP, (BZG),) is a global oil, energy, bank, finance, real estate, top hotel, antique and cultural relics investment enterprise founded by Prince Sheikh Khaled Bin Zayed Al Nahyan. Its “Abu Dhabi sovereign fund”, with a size of $1.3 trillion (10 trillion yuan), once ranked first in the world and now ranks second in the world.

The global refueling chain project launched by the Bin Zayed Group is the first subdivided market project based on block chain technology to solve the problem of gas stations. This project not only solves the problem of expensive refueling, The problem of the number of passengers at gas stations is due to the use of the BBOSS points tool to give all participants more benefits. The global network of global refueling chain projects will make full use of the BBOSS accounting tool, meaning that the physical application of BBOSS tools is rapidly expanding to more areas around the world.

The cooperation with the China Aviation Rescue Alliance also applies the oil chain to people’s livelihood, refueling BBOSS Token to let more consumers feel the convenience and benefits of BBOSS accounting tools to their lives.

Contacts

Jan Liu

Jan@globalnews.com

Continue Reading

Business Wire

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Textron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Business Wire

Published

on

Reading Time: 2 minutes

LOS ANGELES–(BUSINESS WIRE)–$TXT #TXTThe Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Textron Inc. (“Textron” or “the Company”) (NYSE: TXT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s shares between January 31, 2018 and October 17, 2018, inclusive (the ”Class Period”), are encouraged to contact the firm before October 21, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Textron suffered from slowing end-market sales of Arctic Cat products, leaving the sales channel filled with excess inventory. The Company provided significant discounts in an effort to clear the aging inventory, which impacted its earnings. Based on these facts, the Company’s public statements were false and materially misleading. When the market learned the truth about Textron, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Contacts

The Schall Law Firm

Brian Schall, Esq.

www.schallfirm.com

Office: 310-301-3335

Cell: 424-303-1964

info@schallfirm.com

Continue Reading

Business Wire

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Textron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Business Wire

Published

on

Reading Time: 2 minutes

LOS ANGELES–(BUSINESS WIRE)–$TXT #TXTThe Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Textron Inc. (“Textron” or “the Company”) (NYSE: TXT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s shares between January 31, 2018 and October 17, 2018, inclusive (the ”Class Period”), are encouraged to contact the firm before October 21, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Textron suffered from slowing end-market sales of Arctic Cat products, leaving the sales channel filled with excess inventory. The Company provided significant discounts in an effort to clear the aging inventory, which impacted its earnings. Based on these facts, the Company’s public statements were false and materially misleading. When the market learned the truth about Textron, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Contacts

The Schall Law Firm

Brian Schall, Esq.

www.schallfirm.com

Office: 310-301-3335

Cell: 424-303-1964

info@schallfirm.com

Continue Reading

Font Resizer

Subscribe to PICANTE via Email

Enter your email address to subscribe to PICANTE and receive notifications of new posts by email.

Follow us on Facebook

Read more from our authors

Follow our Tweets

Trending

Please turn AdBlock off